# Recursion Pharmaceuticals

Source: https://onco.cc/companies/recursion/  
OnCo record `recursion` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Recursion is an AI-first biotech (merged with Exscientia in 2024) with a clinical oncology pipeline that includes an RBM39 degrader and a MEK inhibitor for familial adenomatous polyposis.

## Summary

Recursion Pharmaceuticals, based in Salt Lake City and listed as RXRX, is an AI-first biotechnology company that merged with Exscientia in 2024, with a clinical oncology pipeline including an RBM39 degrader and a MEK inhibitor for familial adenomatous polyposis. Its programmes include REC-1245, the RBM39 degrader in phase 1/2, REC-4881, a MEK1/2 inhibitor in phase 2 for FAP with FDA registrational discussions, and candidates against LSD1, CDK7, PI3K-alpha H1047R, MALT1 and ENPP1, and it reported revenue shortfalls alongside pipeline progress in the first quarter of 2026. OnCo links it to colorectal cancer, AI-driven discovery and protein degradation, the MAPK and cGAS-STING pathways and the idea of a virtual cancer cell. Whether AI-discovered candidates succeed in the clinic at a higher rate than conventional ones is the question the company exists to test.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Salt Lake City, UT
- Type: ai-software
- Website: https://www.recursion.com
- Ticker: RXRX

## Sources

- Q1 2026 update: https://ir.recursion.com/news-releases/news-release-details/recursion-reports-first-quarter-financial-results-and-provides

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- fronts: [AI & Computation](https://onco.cc/fronts/ai-computation/), [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/)
- technologies: [AI-driven drug & target discovery](https://onco.cc/technologies/ai-drug-design/), [Boltz-1 / Boltz-2 (MIT, open)](https://onco.cc/technologies/boltz/), [Phenom-2 and Recursion OS](https://onco.cc/technologies/phenom-2/), [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)
- targets: [PIK3CA / PI3K-alpha](https://onco.cc/targets/pik3ca/)
- pathways: [cGAS-STING innate sensing](https://onco.cc/pathways/cgas-sting/), [RAS / RAF / MEK / ERK (MAPK)](https://onco.cc/pathways/ras-mapk/)
- trials: [A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer](https://onco.cc/trials/nct06678659/), [Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct05985655/)
- bottlenecks: [Lab models that fail to predict what happens in patients](https://onco.cc/bottlenecks/b-preclinical-models/), [No incentive to repurpose cheap drugs](https://onco.cc/bottlenecks/b-generic-repurposing/), [The valley of death between lab and product](https://onco.cc/bottlenecks/b-translational-valley/)
- ideas: [A virtual cancer cell that predicts what a drug will do before you test it](https://onco.cc/ideas/idea-bio1-virtual-cell-perturbation/), [Self-driving laboratories that run the cancer biology hypothesis loop autonomously](https://onco.cc/ideas/idea-moon-self-driving-cancer-labs/)
- companies: [Exscientia](https://onco.cc/companies/exscientia/)
- roadmaps: [AI in oncology roadmap: pattern readers → foundation models → agents in the workflow](https://onco.cc/roadmaps/ai-oncology-roadmap/), [Drug discovery roadmap: screening in mice → maps of dependency → designing in silico](https://onco.cc/roadmaps/drug-discovery-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/recursion.json